Fig. 3From: Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS studyMean change from BL in the number of headache days of at least moderate severity in the DB period and the OLE (mITT).a BL, baseline; DB, double-blind; OLE, open-label extension; mITT, modified intent-to-treat. aAll patients in the OLE received fremanezumab 225 mg monthlyBack to article page